Paradigmatic was the use of ascorbic acid to treat CMT1A neuropathy: while treatment in mouse model of CMT1A (C22) significantly ameliorated the neuropathic phenotype and reduced Pmp22 level [41], clinical trials in humans failed to show any effect in patients as well as effect on PMP22 expression [228,229,230,231]. The gene discussed is PMP22; the disease is neuropathy.